Skip to main content

Table 2 Oncological characteristics of patients receiving SACT

From: Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

 

2019 (n = 518)

2020 (n = 441)

(n2020n2019)/n2019 (%)

p value

n

%

N

%

Cancer type

 Prostate

340

65.64

292

66.21

14.12

0.851

 Renal

121

23.36

101

22.90

16.53

0.867

 Urothelial

42

8.11

38

8.62

9.52

0.776

 Testicular

15

2.90

10

2.27

33.33

0.543

Stage

 1

7

1.35

2

0.45

71.43

0.161

 2

11

2.12

6

1.36

45.45

0.368

 3

36

6.95

9

2.04

75.00

< 0.0001*

 4

463

89.38

423

95.92

8.64

< 0.0001*

 Missing

1

0.19

1

0.23

0.00

0.271

SACT

 Chemotherapy

112

21.62

71

16.10

36.61

0.0278

 Immunotherapy (IO)

43

8.30

50

11.34

− 16.28

0.110

 Hormone

244

47.10

236

53.51

3.28

0.0455

 Biological/targeted

102

19.69

67

15.19

34.31

0.0574

 Combo (Chemo/hormone)

9

1.74

2

0.45

77.78

0.0574

 Combo (Chemo/IO)

1

0.19

1

0.23

0.00

0.920

 Combo (Chemo/target)

0

0.00

1

0.23

N.A

0.271

 Combo (IO/Hormone)

1

0.19

0

0.00

100.00

0.368

 Combo (IO/target)

5

0.97

13

2.95

− 160.00

0.0214

 Combo (Chemo/IO/hormone)

1

0.19

0

0.00

100.00

0.368

Treatment paradigm

 Neoadjuvant

11

2.12

6

1.36

45.45

0.368

 Adjuvant

17

3.28

6

1.36

64.71

0.0574

 Radical

18

3.47

1

0.23

94.44

0.00194*

 Palliative

470

90.73

419

95.01

10.85

0.0124

 Curative

2

0.39

9

2.04

− 350.00

0.0164

Line of palliative treatment (2019, n = 470; 2020, n = 419)

 1

94

20.00

117

27.92

− 24.47

0.00194*

 2

248

52.77

257

61.34

− 3.63

0.00137*

 3

87

18.51

30

7.16

65.52

 < 0.0001*

 4

26

5.53

10

2.39

61.54

0.0278

 5

11

2.34

3

0.72

72.73

0.0574

 6

2

0.43

2

0.48

0.00

0.841

 7

1

0.21

0

0.00

100.00

0.368

 Missing

1

0.21

0

0.00

100.00

0.368

Trial treatment

 Yes

64

12.36

52

11.79

18.75

0.790

SACT initiated during study period

 Yes

118

22.78

102

23.13

13.56

0.898

  1. *Statistically significant p values after Bonferroni correction for multiple comparisons